Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 known ✓ | P27487 | 2/20 | 0.42 |
| ▸ | CA2 known ✓ | P00918 | 1/20 | 0.38 |
| ▸ | RRM1 known ✓ | P23921 | 1/20 | 0.36 |
| ▸ | GSR | P00390 | 1/20 | 0.47 |
| ▸ | DPP7 | Q9UHL4 | 4/20 | 0.42 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.42 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.42 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.41 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.41 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | TLR2 | O60603 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | ZDHHC7 | Q9NXF8 | 1/20 | 0.36 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.36 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.36 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.36 |
| ▸ | LTA4H | P09960 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3219777 | 1.00 | GSR (0.47) | GSRDPP7DPP8DPP9DPP4 | |
| Hydrochloric Acid SCHEMBL1518387 | 1.00 | GSR (0.47) | GSRDPP7DPP8DPP9DPP4 | |
| Hydrochloric Acid SCHEMBL4812497 | 1.00 | GSR (0.47) | GSRDPP7DPP8DPP9DPP4 | |
| Hydrochloric Acid SCHEMBL3218034 | 1.00 | GSR (0.47) | GSRDPP7DPP8DPP9DPP4 | |
| Hydrochloric Acid SCHEMBL3219768 | 1.00 | GSR (0.47) | GSRDPP7DPP8DPP9DPP4 | |
| SCHEMBL569592 | 0.98 | GSR (0.48) | GSRDPP7DPP8DPP9DPP4 | |
| SCHEMBL569593 | 0.98 | GSR (0.48) | GSRDPP7DPP8DPP9DPP4 | |
| SCHEMBL1518233 | 0.98 | GSR (0.48) | GSRDPP7DPP8DPP9DPP4 | |
| Fluoride SCHEMBL27593971 | 0.96 | GSR (0.47) | GSRDPP7DPP8DPP9DPP4 | |
| Hydrochloric Acid SCHEMBL1518095 | 0.94 | GSR (0.55) | GSRDPP7DPP8DPP9DPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119591749-A | HA-Orn 3D hydrogel for culturing cells to obtain exosomes, and preparation method and application thereof | 中南大学 | 2025-03-11 | — | — | CN | claimed |
| WO-2019076178-A1 | DEGRADATION TIME CONTROLLABLE AND BREAKING ELONGATION ADJUSTABLE MEDICAL DEGRADABLE POLYURETHANE | 凯斯蒂南京医疗器械有限公司 | 2019-04-25 | — | — | WO | claimed |
| CN-119591749-A | HA-Orn 3D hydrogel for culturing cells to obtain exosomes, and preparation method and application thereof | 中南大学 | 2025-03-11 | — | — | CN | disclosed |
| EP-3634430-B1 | MULTIBIOTIC AGENTS AND METHODS OF USING THE SAME | FLAGSHIP PIONEERING INNOVATIONS V INC (US) | 2024-08-07 | — | — | EP | disclosed |
| CN-116829949-A | Compositions for detecting or measuring analytes | 伯蒂斯有限公司 | 2023-09-29 | — | — | CN | disclosed |
| US-20230293458-A1 | MULTIBIOTIC AGENTS AND METHODS OF USING THE SAME | FLAGSHIP PIONEERING INNOVATIONS V INC (US) | 2023-09-21 | — | — | US | disclosed |
| WO-2023075435-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTE | 주식회사 베르티스 | 2023-05-04 | — | — | WO | disclosed |
| US-20220283131-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTES | BERTIS CO., LTD. (KR) | 2022-09-08 | — | — | US | disclosed |
| WO-2022050529-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTE | ㈜베르티스 | 2022-03-10 | — | — | WO | disclosed |
| EP-3818995-A1 | DEGRADABLE SPIRAL COATED STENT WITH CONTROLLABLE GRADIENT, PREPARATION METHOD THEREFOR AND USE THEREOF | Zhuhai Ruizhan Biomaterials Co., Ltd. (CN) | 2021-05-12 | — | — | EP | disclosed |
| US-20210128795-A1 | SPIRAL COATED STENT WITH CONTROLLABLE GRADIENT DEGRADATION, PREPARATION METHOD THEREOF AND APPLICATION THEREOF | ZHUHAI RUIZHAN BIOMATERIALS CO LTD (CN) | 2021-05-06 | — | — | US | disclosed |
| US-5274089-A | A estra-1,3,5(10)-triene derivative | THE UPJOHN COMPANY (US) | 1993-12-28 | — | — | US | disclosed |
| US-5196542-A | Phospholipase A2 inhibitors | THE UPJOHN COMPANY (US) | 1993-03-23 | — | — | US | disclosed |
| US-5187299-A | Phospholipase inhibitors; treating diabetes, obesity | THE UPJOHN COMPANY (US) | 1993-02-16 | — | — | US | disclosed |
| US-5145874-A | Phospholipase inhibitor, hypoglycemic agent, antidiabetic, obesity | THE UPJOHN COMPANY (US) | 1992-09-08 | — | — | US | disclosed |
| US-5051509-A | Antibiotics | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 1991-09-24 | — | — | US | disclosed |
| US-4917826-A | TREATING DIABETES AND OBESITY | THE UPJOHN COMPANY (US) | 1990-04-17 | — | — | US | disclosed |
| EP-0342675-A2 | Novel quinolonecarboxylic acid derivatives | Chugai Seiyaku Kabushiki Kaisha (JP) | 1989-11-23 | — | — | EP | disclosed |
| US-4330559-A | 2,5-DIAMINO-2-FLUOROMETHYLPENTANOIC ACIDS OR DERIVATIVES | MERRELL-TORAUDE ET CIE (FR) | 1982-05-18 | — | — | US | disclosed |
| US-4309442-A | 2,5-DIAMINO-2-FLUOROMETHYLPENTANOIC ACID OR DERIVATIVE THEREOF | MERRELL TORAUDE ET COMPAGNIE (FR) | 1982-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230293458-A1 | MULTIBIOTIC AGENTS AND METHODS OF USING THE SAME | SI, FABP2, CEL | DPP4 400/4885CA2 504/4885RRM1 3871/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.